Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer

Purpose This study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer. Methods Fifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-rand...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer Vol. 25; no. 9; pp. 2771 - 2777
Main Authors: Korkeila, E. A., Salminen, T., Kallio, R., Mikkola, M., Auvinen, P., Pyrhönen, S., Ristamäki, R.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-09-2017
Springer
Springer Nature B.V
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Capecitabine - administration & dosage
Capecitabine - pharmacology
Capecitabine - therapeutic use
Care and treatment
Chemotherapy
Disease Progression
Docetaxel
Drug therapy
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Female
Gastrointestinal diseases
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Nursing
Nursing Research
Oncology
Original
Original Article
Pain Medicine
Palliative care
Prospective Studies
Quality of life
Quality of Life - psychology
Rehabilitation Medicine
Stomach cancer
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Taxoids - administration & dosage
Taxoids - pharmacology
Taxoids - therapeutic use
Chemotherapy
Palliative treatment
Advanced gastro-oesophageal cancer
Quality of life
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose This study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer. Methods Fifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-randomized, multicentre phase II trial to receive intravenous docetaxel 50 mg/m 2 on days 1 and 15, and oral capecitabine 1250 mg/m 2 every 12 h, on days 1–7 and 15–21 of each 28-day cycle. QOL was assessed using EORTC QLQ-C30, together with the gastric module (QLQ-STO 22). Results Forty-six patients were evaluable for QOL analyses. No deterioration in global health status was found. Social functioning scores improved, and eating difficulties and pain were alleviated during treatment. The most common grade 3 or 4 toxicity was neutropenia (47%), whereas neutropenic fever was uncommon (6%). The clinical benefit rate was 60%, including complete and partial responses as well as stabilized disease. Median overall survival was 8.8 months (95% CI 5.8–11.9 months), and median time to progression was 6.2 months (95% CI 4.9–7.5 months). Conclusions Biweekly docetaxel with capecitabine is a feasible treatment in AGC, delivered on an outpatient basis, with no need for central venous access device. No deterioration of global health status was reported. In addition, pain and eating difficulties were alleviated during study treatment. This trial is registered at ClinicalTrials.gov , number NCT00669370.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-017-3689-5